Skip to main content

Table 3 Overall survival in patients with high-grade salivary gland cancers (n = 124)

From: Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1–2 N0 high-grade salivary gland cancer

Factors (Number) Univariate model Multivariate model #1 Multivariate model #2
HR 95% CI P HR 95% CI P HR 95% CI P
 Age (years) 1.032 1.005–1.059 0.019 1.038 1.008–1.069 0.012 1.054 1.024–1.084 < 0.001
 Gender (Male/Female) (95/29) 1.396 0.645–3.022 0.397       
 Primary site
  Parotid gland (84) 1 (Ref.)         
  Non-parotid gland (40) 1.286 0.687–2.405 0.432       
 TNM categories
  T3–4/T1–2 (60/64) 1.785 0.955–3.336 0.069 0.807 0.405–1.609 0.542 0.964 0.505–1.839 0.912
  N1–3/N0 (61/63) 5.002 2.492–10.042 < 0.001 9.263 4.025–21.317 < 0.001 7.010 3.176–15.472 < 0.001
  M1/M0 (15/109) 4.171 1.978–8.795 < 0.001     4.716 2.148–10.357 < 0.001
 Pathological diagnosis
  Salivary duct carcinoma (74) 1 (Ref.)         
  Squamous cell carcinoma, primary (13) 1.434 0.582–3.534 0.433       
  Adenoid cystic carcinoma, solid type (12) 1.381 0.523–3.646 0.515       
  Mucoepidermoid carcinoma, high-grade (9) 1.458 0.501–4.246 0.489       
  Adenocarcinoma, high-grade (6) 0.370 0.050–2.752 0.332       
  Others* (10) 2.059 0.707–5.999 0.186       
 Treatment modalities
  Surgery (13) 1 (Ref)    1 (Ref.)      
  Surgery + radiation (62) 0.945 0.355–2.514 0.909 0.720 0.254–2.044 0.537    
  Surgery + radiation + chemotherapy (28) 0.299 0.070–1.276 0.103 0.158 0.033–0.755 0.021    
  Others (21) 3.282 1.115–9.655 0.031 1.793 0.374–8.602 0.466    
  1. M1 status was significantly associated with the application of the so-called other treatment modalities (initial non-surgical, chemotherapy or palliative treatments); thus, we built two separate multivariate models using independent variables
  2. Abbreviation:
  3. HR hazard ratio, CI confidence interval
  4. Others*: Atypical high-grade carcinoma, high-grade carcino-sarcoma, poorly differentiated carcinoma
  5. Others†: Initial non-surgical local treatment (radiation or chemoradiation), chemotherapy or palliative treatment